AbbVie Inc. Net Cash/Marketcap

Net Cash/Marketcap of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Cash/Marketcap growth rates and interactive chart.


Highlights and Quick Summary

Current Net Cash/Marketcap of AbbVie Inc. is $0.416 (as of December 30, 2020)
  • Net Cash/Marketcap for the quarter ending September 29, 2021 was $0.359 (a -2.84% decrease compared to previous quarter)
  • Year-over-year quarterly Net Cash/Marketcap decreased by -13.69%
  • Annual Net Cash/Marketcap for 2020 was $0.416 (a 103.28% increase from previous year)
  • Annual Net Cash/Marketcap for 2019 was $0.204 (a -9.96% decrease from previous year)
  • Annual Net Cash/Marketcap for 2018 was $0.227 (a 29.27% increase from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Cash/Marketcap of AbbVie Inc.

Most recent Net Cash/Marketcapof ABBV including historical data for past 10 years.

Interactive Chart of Net Cash/Marketcap of AbbVie Inc.

AbbVie Inc. Net Cash/Marketcap for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.0 $0.0 $0.0
2020 $0.0 $0.0 $0.0 $0.0 $0.0
2019 $0.0 $0.0 $0.0 $0.0 $0.0
2018 $0.0 $0.0 $0.0 $0.0 $0.0
2017 $0.0 $0.0 $0.0 $0.0 $0.0
2016 $0.0 $0.0 $0.0 $0.0 $0.0
2015 $0.0 $0.0 $0.0 $0.0 $0.0
2014 $0.0 $0.0 $0.0 $0.0 $0.0
2013 $0.0 $0.0 $0.0 $0.0 $0.0
2012 $0.0 $0.0 $0.0 $0.0 $0.0
2011 $0.0 $0.0 $0.0 $0.0 $0.0
2010 $0.0

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.